Abstract: Provided herein are methods and compositions for editing the genome of a cell. In some embodiments, a nucleotide sequence of at least 200 nucleotides in length is inserted into a target region in the genome of a cell.

Abstract: Provided herein are genetically modified T cells that exhibit increased proliferation compared to wild-type T cells when stimulated, methods of generating such T cells, and methods of using the T cells for the treatment of a disease such as cancer.

Abstract: Aspects of the present disclosure involve implementations that may be used to protect neural network models against adversarial attacks by obfuscating neural network operations and architecture. Obfuscation techniques include obfuscating weights and biases of neural network nodes, obfuscating activation functions used by neural networks, as well as obfuscating neural network architecture by introducing dummy operations, dummy nodes, and dummy layers into the neural networks.

Abstract: Disclosed aspects and implementations are directed to systems and techniques for protecting cryptographic operations against side-channel attacks. In one example, polynomials associated with secret data and public data defined on a working domain having a first dimension are mapped to an auxiliary domain having a larger second dimension. The mapped polynomials are masked using masking polynomials associated with a kernel of a homomorphism transformation from the auxiliary domain to the working domain. One or more computations are then performed on the masked polynomials in the auxiliary domain and an output is transformed from the auxiliary domain to the working domain.

Abstract: The present disclosure provides a cargo delivery fusion polypeptide comprising an endosomolytic polypeptide and a cell penetrating polypeptide; and compositions comprising the cargo delivery fusion polypeptide. The present disclosure also provides methods of delivering a cargo into a target eukaryotic cell, using a composition comprising an amphiphilic polypeptide.

Abstract: Provided herein are compositions and methods for modifying T cells. The disclosure is based, in part, on the use of sgRNA lentiviral infection with Cas9 protein electroporation (SLICE), to identify regulators of IL2RA, IL-2, CTLA4, arnd FOXP3 in effector T cells. IL2RA, IL-2, CTLA4, and FOXP3 are key genes in immune regulation that have been implicated in autoimmune disease and cancer. Therefore, modulating expression of these genes in T cells, for example, effector T cells or regulatory T cells, could have therapeutic applications.

Abstract: Provided herein are methods and compositions for modifying the genome of human T cells.

Abstract: This disclosure generally relates to high-throughput and modular methods and compositions for barcode-trackable cellular receptor design, manufacture, and measurement.

Abstract: Provided herein are methods and compositions for editing the genome of a cell. In some embodiments, a nucleotide sequence of at least 200 nucleotides in length is inserted into a target region in the genome of a cell.

Abstract: Described herein are positive and negative regulators of BTN3A, as well as methods for identifying subjects who can benefit from T cell therapies and/or various chemotherapies. The subjects can for example be suffering from immune disorders, cancer and other diseases and conditions.

Abstract: Provided herein are methods and compositions for editing the genome of a cell. In some embodiments, a nucleotide sequence of at least 200 nucleotides in length is inserted into a target region in the genome of a cell.

Abstract: This disclosure relates to chimeric receptors (CRs) and their signaling components for the regulation of an immune response. Also provided are nucleic acids encoding the disclosed CRs, recombinant immune cells expressing the same, and pharmaceutical compositions containing the disclosed nucleic acids and/or recombinant cells.

Abstract: Provided herein are methods and compositions for editing the genome of a human T cell. In some embodiments, a heterologous T cell receptor (TCR)-? chain and a heterologous TCR-? chain are inserted into exon 1 of a TCR subunit constant gene in the genome of the T cell.

Abstract: The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway.

Abstract: Provided herein are compositions and methods for altering sensitivity of target cells to killing by ?? T cells.

Abstract: The present disclosure generally relates to spatial detection of a nucleic acid, such as a genomic DNA or a RNA transcript, in a cell comprised in a tissue sample. The present disclosure provides methods for detecting and/or analyzing nucleic acids, such as chromatin or RNA transcripts, so as to obtain spatial information about the localization, distribution or expression of genes in a tissue sample. The present disclosure thus provides a process for performing “spatial transcriptomics” or “spatial genomics,” which enables the user to determine simultaneously the expression pattern, or the location/distribution pattern of the genes expressed or genes or genomic loci present in a single cell while retaining information related to the spatial location of the cell within the tissue architecture.

Abstract: The disclosure provides compositions and methods for modifying a target nucleic acid that use a donor construct including at least one donor template comprising a single-stranded homology directed repair template (ssHDRT) and one or more DNA-binding protein target sequences, in which at least one DNA-binding protein target sequence forms a double-stranded duplex with a complementary polynucleotide sequence.

Abstract: Methods are described herein for isolating clonal populations of T cells having a defined genetic modification. The methods are performed, at least in part, in a microfluidic device comprising one or more sequestration pens. The methods include the steps of: maintaining individual T cells (or precursors thereof) that have undergone a genomic editing process in corresponding sequestration pens of a microfluidic device; expanding the T cells into respective clonal populations of T cells; detecting, in one or more T cells of each clonal population, the absence of a cell surface marker that was present in the individual T cells (or precursors thereof); and detecting, in one or more T cells of each clonal population, the presence of a first nucleic acid sequence that is indicative of the presence of an on-target genome edit in the clonal population of T cells. Also described are compositions comprising one or more clonal populations of T cells isolated according to the methods disclosed herein.

Abstract: The disclosure provides compositions and methods for for modifying an endogenous cell surface protein (e.g., an endogenous TCR) in a cell (e.g., a T cell) with a CAR or an exogenous protein (e.g., an exogenous intracellular or cell surface protein (e.g., an exogenous TCR)).

Abstract: Provided herein are methods and compositions for identifying a targeted genomic insertion in a cell. Also provided are heterologous polypeptides that are co-expressed under the control of enodogenous loci and methods of using same.